Clinical trials: Obese Diabetics
Diabetes, Obesity
Role of Methane in Glycemic Control
The purpose of this study is to determine how certain types of bacteria in the human gut may affect weight gain, and contribute to the development of diabetes.
- Trial name
- NCT01638429
- Testing
- Neomycin, Rifaximin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Cedars-Sinai Medical Center
Type 2 Diabetes or Obesity Without Diabetes
Search for Biological Markers of Orosensory Perception of Fatty Acids in Healthy Subjects and Possible Modifications in Patients With Type 2 Diabetes and in Obese Non-diabetic Patients.
Animal studies have shown that stimulation of the lingual lipid-receptor, CD 36, is accompanied by the rapid secretion of hormones in the digestive tract (incretines).
- Trial name
- NCT02028975
- Testing
- Measure the threshold of detection for linoleic acid, Oral stimulation tests, Venous blood samples
- Where
- France
- Volunteers
- 81 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Obesity, Pre-diabetic
Personalized Glucose Optimization Through Nutritional Intervention
Maintaining well-controlled blood glucose concentrations is essential in the prevention of chronic cardiometabolic diseases. The blood glucose response to dietary and/or lifestyle patterns may vary between individuals.
- Conditions
- Obesity, Pre-diabetic, Type 2 Diabetes Mellitus
- Trial name
- PERSON (NCT03708419)
- Testing
- Optimal diet, Suboptimal diet
- Where
- 2 sites in Netherlands
- Volunteers
- 242 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Obesity, Type 2 Diabetes
EndoBarrier® SANS™ in Over-weight or Obese Type 2 Diabetic Subjects
This study will evaluate the safety and efficacy of the EndoBarrier® SANS™ in overweight and obese subjects with type 2 diabetes.
- Trial name
- NCT02443753
- Testing
- EndoBarrier SANS
- Where
- Malaysia
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Morphic Medical Inc.
Overweight or Obesity
A Study of TG103 Injection in Non-diabetic Overweight or Obesity
This study is a multicenter, randomized, double-blind, placebo-controlled, parallel phase 3 study to evaluate efficacy, safety, pharmacokinetics characteristics and immunogenicity of TG103 injection, a GLP-1 receptor agonist, for…
- Trial name
- NCT05997576
- Testing
- TG103 22.5 mg
- Where
- China
- Volunteers
- 675 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Overweight , Obesity
Phase 2 Study of MWN109 Tablet for Weight-Loss Maintenance in Participants With Overweight or Obesity
This study adopted a randomized, open-label design, aiming to preliminarily explore the weight-loss maintenance effect of MWN109 tablets when administered continuously for 24 weeks in non-diabetic overweight or obese…
- Trial name
- NCT07804797
- Testing
- MWN109 1, MWN109 2
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Liver Biomarkers, Glucose
Modulatory Effects of Resveratrol Supplement Along With and Without Low Glycemic Index Diet Among Obese Patients With Diabetic Nephropathy
This 12-week randomized controlled trial evaluated the effects of resveratrol supplementation with and without a low glycemic index (LGI) diet in obese patients with diabetic nephropathy.
- Conditions
- Liver Biomarkers, Glucose, Lipid Profiles
- Trial name
- NCT07891975
- Testing
- T0 starch capsule, T1 resveratrol capsule, T2 300 mg per day along with a low glycemic index diet, TWICE A DAY
- Where
- Pakistan
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- University of Lahore
Obesity, Diabetes Mellitus, Type 2
A Study of the Safety and Efficacy of Topiramate in the Treatment of Obese, Type 2 Diabetes Patients on a Controlled Diet
The purpose of this study is to determine the efficacy and safety of topiramate compared with placebo in obese, Type 2 diabetic patients on a controlled diet.
- Conditions
- Obesity, Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
- Trial name
- NCT00231530
- Testing
- topiramate
- Volunteers
- 541 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Diabete Type 2, Obesity
The GATE Study: Endoscopic Sutured Gastroplasty in Type 2 Diabetic, Obese Patients Using the Endomina Device
Rationale: Diabetes mellitus is a chronic disease that is often associated with long-term macrovascular and microvascular complications and decreased life expectancy.
- Trial name
- GATE (NCT05599477)
- Testing
- Endoscopic sutured gastroplasty with endomina
- Volunteers
- 40 people
- Sponsor
- Radboud University Medical Center
Metabolic Syndrome X
Weight Loss in Diabetic, Older Obese Adults
This study examines the effects of weight loss and aerobic exercise training on sugar metabolism and other risk factors for heart disease in obese older individuals.
- Trial name
- NCT00108329
- Testing
- Weight Loss
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Obesity, Diabetes Mellitus, Type 2
A Study of the Efficacy and Safety of Topiramate in the Treatment fo Obese, Type 2 Diabetic Patients Treated With Metformin
The purpose of this study is to compare the efficacy (in terms of weight and hemoglobin type A1c [HbA1c]) and safety of topiramate (96 milligrams[mg] or 192 mg daily) with placebo in the treatment of obesity in Type 2 diabetic…
- Conditions
- Obesity, Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
- Trial name
- NCT00231660
- Testing
- topiramate
- Volunteers
- 211 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Diabetes Mellitus, Type 2, Kidney Disease, Chronic
Randomized Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease
Proven therapy for DKD is primarily limited to RAAS blockers and SLGT2i. Weight reduction has the potential to become an additional and much needed treatment option.
- Conditions
- Diabetes Mellitus, Type 2, Kidney Disease, Chronic, Kidney Injury
- Trial name
- OBESE-DKD (NCT04626323)
- Testing
- Roux-en-Y gastric bypass, Best medical treatment
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Hospital Alemão Oswaldo Cruz
Adolescent Obesity
Antrum Size, Glucagon-like Peptide 1 Levels and Glycemic Control After Sleeve Gastrectomy in Morbid Obese Diabetic Adolescents
Childhood obesity can adversely affect every organ and often has serious consequences. Compare the effect of transection at 2cm vs at 5cm from the pylorus during laparoscopic sleeve gastrectomy on the postoperative weight loss…
- Trial name
- NCT04388059
- Testing
- Laparoscopic sleeve gastrectomy
- Volunteers
- 18 people
- Sponsor
- Tanta University
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients
Type 2 Diabetes Mellitus (T2DM) is a progressive metabolic disease, often compounded by obesity, that leads to serious long-term health complications.
- Trial name
- NCT07728318
- Testing
- Tirzepatide + Standard Therapy (Intervention Group), Standard Oral Antidiabetic Drugs (OADs)
- Volunteers
- 52 people
- Sponsor
- Akhtar Saeed Medical and Dental College
1- Microvascular Function, 2-oxidative Stress
Acute and Short-term Chronic Effects of Galvus (Vildagliptin) in Diabetes Type 2 Obese Women
The prevalence of obesity and type 2 diabetes mellitus (T2DM) has increased progressively in the past decades, and consequently, a higher incidence of cardiovascular diseases is observed.
- Conditions
- 1- Microvascular Function, 2-oxidative Stress, 3-inflammation
- Trial name
- NCT01827280
- Testing
- Vildagliptin
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- Rio de Janeiro State University
Obesity, Weight Reduction
Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults
This prospective, open-label, single-arm, single-center interventional pilot trial aims to evaluate the efficacy and safety of low-dose semaglutide for weight loss and cardiometabolic improvement in obese Pakistani adults without…
- Conditions
- Obesity, Weight Reduction, Cardiometabolic Risk Factors
- Trial name
- NCT07513168
- Testing
- Locally available low-dose semaglutide (0.25 mg, 0.5 mg, 1 mg)
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Asian Institute Of Medical Sciences
Type 2 Diabetes
High Protein Breakfast on Appetite, Postprandial Glycemia and Weight Loss in T2D
The investigators hypothesis is that eating whey protein in the breakfast versus other proteins will results in higher satiety, reduced overall postprandial glycemia and more weight loss in obese diabetic individuals
- Trial name
- HPB (NCT01623648)
- Testing
- Arm 1 Whey Breakfast, Arm 2 No Whey Breakfast, Arm 3 Low Protein Breakfast
- Where
- 2 sites in Israel, Venezuela
- Volunteers
- 58 people
- Sponsor
- Hospital de Clinicas Caracas
Type 2 Diabetes Mellitus, Obesity
Effect of Gastric Bypass Surgery on Diabetes Status and Microvascular Complications in Obese Type 2 Diabetic Patients
This study evaluates the long-term benefits of Roux-en-Y gastric bypass (RYGB) on type 2 diabetes mellitus, focussing on the prevalence and predictors of T2DM improvement and remission after RYGB, and subsequently relapse of type…
- Conditions
- Type 2 Diabetes Mellitus, Obesity, Diabetic Retinopathy, Diabetic Nephropathy
- Trial name
- NCT02625649
- Where
- Denmark
- Volunteers
- 148 people
- Sponsor
- University of Aarhus
Diabetic Foot Ulcer
Effect of Adiposity and Associated Local Microbial Factors on Healing and Progression of Diabetic Foot Ulcers
Diabetic foot ulcers (DFUs) and their associated complications like amputations are increasingly becoming a problem in low and middle income (LMI) countries.
- Trial name
- NCT03960255
- Testing
- Normal standard care
- Where
- 4 sites in Tanzania
- Volunteers
- 300 people
- Sponsor
- Muhimbili University of Health and Allied Sciences
Obesity, Pre-diabetes
Evaluation of Lifestyle Interventions to Treat Elevated Cardiometabolic Risk in Primary Care
The purpose of the E-LITE Study is to evaluate the feasibility and potential effectiveness of two lifestyle interventions in a community based primary care setting.
- Conditions
- Obesity, Pre-diabetes, Metabolic Syndrome
- Trial name
- E-LITE (NCT00842426)
- Testing
- Self-management program (SM), Care management program (CM)
- Where
- United States
- Volunteers
- 241 people
- Sponsor
- Palo Alto Medical Foundation